Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10: Results of a prospective cohort study

Mark A. Crowther; David Garcia; Walter Ageno; Luqi Wang; Dan M. Witt; Nathan P. Clark; Mark D. Blostein; Susan R. Kahn; Sam Schulman; Michael Kovacs; Marc A. Rodger; Philip Wells; David Anderson; Jeffrey Ginsberg; Rita Selby; Sergio Siragusa; Mauro Silingardi; Mary Beth B. Dowd; Clive Kearon

doi:10.1160/TH09-12-0822

Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10: Results of a prospective cohort study

Mark A. Crowther, David Garcia, Walter Ageno, Luqi Wang, Dan M. Witt, Nathan P. Clark, Mark D. Blostein, Susan R. Kahn, Sam Schulman, Michael Kovacs, Marc A. Rodger, Philip Wells, David Anderson, Jeffrey Ginsberg, Rita Selby, Sergio Siragusa, Mauro Silingardi, Mary Beth B. Dowd, Clive Kearon

Résultat de recherche: Article › examen par les pairs

32 Citations (Scopus)

Résumé

Unanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarintreated patients with INR values of more than 10 who received a single 2.5 mg dose of oral vitamin K. During the first week, one patient experienced major bleeding, and one died. In the first 90 days after enrolment four patients had major bleeding (3.7%, 1.0% to 9.3%), eight patients (7.5%, 3.3% to 14.2%) died and two had objectively confirmed thromboembolism. Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding.

Langue d'origine	English
Pages (de-à)	118-121
Nombre de pages	4
Journal	Thrombosis and Haemostasis
Volume	104
Numéro de publication	1
DOI	https://doi.org/10.1160/TH09-12-0822
Statut de publication	Published - juill. 2010
Publié à l'externe	Oui

ASJC Scopus Subject Areas

Hematology

Accès au document

10.1160/TH09-12-0822

Autres fichiers et liens

Citer

Crowther, M. A., Garcia, D., Ageno, W., Wang, L., Witt, D. M., Clark, N. P., Blostein, M. D., Kahn, S. R., Schulman, S., Kovacs, M., Rodger, M. A., Wells, P., Anderson, D., Ginsberg, J., Selby, R., Siragusa, S., Silingardi, M., Dowd, M. B. B., & Kearon, C. (2010). Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10: Results of a prospective cohort study. Thrombosis and Haemostasis, 104(1), 118-121. https://doi.org/10.1160/TH09-12-0822

Crowther, MA, Garcia, D, Ageno, W, Wang, L, Witt, DM, Clark, NP, Blostein, MD, Kahn, SR, Schulman, S, Kovacs, M, Rodger, MA, Wells, P, Anderson, D, Ginsberg, J, Selby, R, Siragusa, S, Silingardi, M, Dowd, MBB & Kearon, C 2010, 'Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10: Results of a prospective cohort study', Thrombosis and Haemostasis, vol. 104, n° 1, pp. 118-121. https://doi.org/10.1160/TH09-12-0822

@article{00eb82760766441b83ce4ec4a2398052,

title = "Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10: Results of a prospective cohort study",

abstract = "Unanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarintreated patients with INR values of more than 10 who received a single 2.5 mg dose of oral vitamin K. During the first week, one patient experienced major bleeding, and one died. In the first 90 days after enrolment four patients had major bleeding (3.7%, 1.0% to 9.3%), eight patients (7.5%, 3.3% to 14.2%) died and two had objectively confirmed thromboembolism. Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding.",

author = "Crowther, {Mark A.} and David Garcia and Walter Ageno and Luqi Wang and Witt, {Dan M.} and Clark, {Nathan P.} and Blostein, {Mark D.} and Kahn, {Susan R.} and Sam Schulman and Michael Kovacs and Rodger, {Marc A.} and Philip Wells and David Anderson and Jeffrey Ginsberg and Rita Selby and Sergio Siragusa and Mauro Silingardi and Dowd, {Mary Beth B.} and Clive Kearon",

year = "2010",

month = jul,

doi = "10.1160/TH09-12-0822",

language = "English",

volume = "104",

pages = "118--121",

journal = "Thrombosis and Haemostasis",

issn = "0340-6245",

publisher = "Schattauer GmbH",

number = "1",

}

TY - JOUR

T1 - Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10

T2 - Results of a prospective cohort study

AU - Crowther, Mark A.

AU - Garcia, David

AU - Ageno, Walter

AU - Wang, Luqi

AU - Witt, Dan M.

AU - Clark, Nathan P.

AU - Blostein, Mark D.

AU - Kahn, Susan R.

AU - Schulman, Sam

AU - Kovacs, Michael

AU - Rodger, Marc A.

AU - Wells, Philip

AU - Anderson, David

AU - Ginsberg, Jeffrey

AU - Selby, Rita

AU - Siragusa, Sergio

AU - Silingardi, Mauro

AU - Dowd, Mary Beth B.

AU - Kearon, Clive

PY - 2010/7

Y1 - 2010/7

N2 - Unanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarintreated patients with INR values of more than 10 who received a single 2.5 mg dose of oral vitamin K. During the first week, one patient experienced major bleeding, and one died. In the first 90 days after enrolment four patients had major bleeding (3.7%, 1.0% to 9.3%), eight patients (7.5%, 3.3% to 14.2%) died and two had objectively confirmed thromboembolism. Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding.

AB - Unanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarintreated patients with INR values of more than 10 who received a single 2.5 mg dose of oral vitamin K. During the first week, one patient experienced major bleeding, and one died. In the first 90 days after enrolment four patients had major bleeding (3.7%, 1.0% to 9.3%), eight patients (7.5%, 3.3% to 14.2%) died and two had objectively confirmed thromboembolism. Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding.

UR - http://www.scopus.com/inward/record.url?scp=77954360557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954360557&partnerID=8YFLogxK

U2 - 10.1160/TH09-12-0822

DO - 10.1160/TH09-12-0822

M3 - Article

C2 - 20458438

AN - SCOPUS:77954360557

SN - 0340-6245

VL - 104

SP - 118

EP - 121

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

IS - 1

ER -

Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10: Results of a prospective cohort study

Résumé

ASJC Scopus Subject Areas

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer